Literature DB >> 7508725

The costs of treating febrile neutropenia in six U.K. Hospitals.

B Leese1.   

Abstract

The cost of treating an episode of febrile neutropenia (FNE) in patients with solid tumours was estimated from the expert opinions of six consultant oncologists in six hospitals in England. Hospital, antibiotic, therapeutic and diagnostic test costs were collected. Hospitalisation, representing 62% of costs, was the largest single factor contributing to the mean cost per FNE of 1541 pounds. If granulocyte colony-stimulating factor (filgrastim) can reduce the length of stay of such patients, then the savings will partly offset the cost of the drug.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7508725     DOI： 10.1016/0959-8049(93)90611-i

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  13 in total

Review 1.  Outpatient therapy for febrile neutropenia: clinical and economic implications.

Authors:  Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.

Authors:  J Hutton; R Brown; M Borowitz; K Abrams; M Rothman; A Shakespeare
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

3.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  The costs of treating febrile neutropenia in patients with malignant blood disorders.

Authors:  B Leese; R Collin; D J Clark
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

5.  Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

Authors:  T N Flynn; S M Kelsey; D L Hazel; J F Guest
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

6.  Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.

Authors:  C A Uyl-de Groot; E Vellenga; E G de Vries; B Löwenberg; G J Stoter; F F Rutten
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

7.  Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas.

Authors:  V C Costa; M B Ferraz; A S Petrilli; C A Pereira; J W Rogerio
Journal:  Support Care Cancer       Date:  2003-04-26       Impact factor: 3.603

8.  Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.

Authors:  J A Paladino; L D Fong; A Forrest; R Ramphal
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

9.  The economic burden of supportive care of cancer patients.

Authors:  Linda S Elting; Ya-Chen Tina Shih
Journal:  Support Care Cancer       Date:  2004-02-07       Impact factor: 3.603

Review 10.  Economic burden of haematological adverse effects in cancer patients: a systematic review.

Authors:  S Y Liou; J M Stephens; K T Carpiuc; W Feng; M F Botteman; J W Hay
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.